{"organizations": [], "uuid": "052f035c9bfe823a287a9bbf46af0047e4754f25", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180529.html", "section_title": "Archive News &amp; Video for Tuesday, 29 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/aurobindo-pharm-results/indias-aurobindo-pharma-q4-profit-misses-estimates-idUSL3N1SZ49L", "country": "US", "domain_rank": 408, "title": "India's Aurobindo Pharma Q4 profit misses estimates", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-28T22:08:00.000+03:00", "replies_count": 0, "uuid": "052f035c9bfe823a287a9bbf46af0047e4754f25"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/aurobindo-pharm-results/indias-aurobindo-pharma-q4-profit-misses-estimates-idUSL3N1SZ49L", "ord_in_thread": 0, "title": "India's Aurobindo Pharma Q4 profit misses estimates", "locations": [], "entities": {"persons": [{"name": "aby jose koilparambil", "sentiment": "none"}, {"name": "arnab paul", "sentiment": "none"}, {"name": "edmund blair", "sentiment": "none"}], "locations": [{"name": "india", "sentiment": "none"}], "organizations": [{"name": "aurobindo pharma ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "aurobindo pharma", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 28 (Reuters) - India’s Aurobindo Pharma Ltd posted a 0.6 percent fall in fourth-quarter net profit on Monday that missed analysts’ estimates.\nNet profit came in at 5.29 billion rupees ($78.49 million) in the quarter ended March 31, compared with 5.32 billion rupees a year earlier, the Hyderabad-headquartered drugmaker said bit.ly/2seX1J4.\nAnalysts on average had expected a profit of 5.98 billion rupees, according to Thomson Reuters data.\nNet sales rose over 11 percent to 39.89 billion rupees.\n$1 = 67.3950 Indian rupees Reporting By Arnab Paul and Aby Jose Koilparambil in Bengaluru Editing by Edmund Blair\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://instagram.com/reuters/", "https://www.youtube.com/user/ReutersVideo", "http://bit.ly/2seX1J4."], "published": "2018-05-28T22:08:00.000+03:00", "crawled": "2018-05-30T11:14:18.000+03:00", "highlightTitle": ""}